Do you want to read an article? Please log in or register.
Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis
Hepatology
Indications
Related content
Hepatology
A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis
Gastroenterology
Marsh TL, Parikh ND, Roberts LR, Schwartz ME, Nguyen MH, Befeler A, Page-Lester S, Tayob N, Srivastava S, Rinaudo JA, Singal AG, Reddy KR, Marrero JA
doi: 10.1053/j.gastro.2024.09.008
Gastrointestinal Cancer
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Lancet
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM, LEAP-012 investigators
doi: 10.1016/S0140-6736(24)02575-3
Gastrointestinal Cancer
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models
J Gastroenterol Hepatol
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T, Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
doi: 10.1111/jgh.16871
Gastrointestinal CancerHepatology
CiThroModel Improves Prediction of Symptomatic Venous Thromboembolism in Hospitalized Patients With Cirrhosis Without Hepatocellular Carcinoma
United European Gastroenterol J
Zanetto A, Vitale A, Pelizzaro F, Simeon V, Campello E, Turco L, Balcar L, Russo FP, Burra P, Simioni P, Senzolo M
doi: 10.1002/ueg2.12758
Gastrointestinal CancerHepatology
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
Gut
Lai JC, Yang B, Lee HW, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Duràn R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castera L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gómez M, Kim SU, Wong VW, Yip TC
doi: 10.1136/gutjnl-2025-334981
Gastrointestinal Cancer
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study
Lancet Gastroenterol Hepatol
Mahajan UM, Oehrle B, Goni E, Strobel O, Kaiser J, Grützmann R, Werner J, Friess H, Gress TM, Seufferlein TW, Uhl W, Will U, Neoptolemos JP, Wittel UA, Vornhülz M, Sirtl S, Beyer G, Regel I, Boeck S, Heinemann V, Frost F, Steveling A, Völzke H, Petersmann A, Nauck M, Weber E, Kamlage B, Lerch MM, Mayerle J, METAPAC trial investigators
doi: 10.1016/S2468-1253(25)00056-1
Inflammatory Bowel Disease
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials
Clin Gastroenterol Hepatol
Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, Steinlauf A, Schwartz D, Feng T, Dubcenco E, Anyanwu SI, Laroux FS, Cunneen C, Powell N
doi: 10.1016/j.cgh.2024.08.032
Hepatology
Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC
Clin Gastroenterol Hepatol
Parikh ND, Jones P, Salgia R, Bhan I, Grinspan LT, Jou JH, Zhou K, Jalal P, Roccaro G, Rangnekar AS, Benhammou JN, Pillai A, Mehta N, Wedd J, Yang JD, Kim AK, Duarte-Rojo A, Oloruntoba OO, Tevar A, Au JS, Blain Y, Rao S, Catalano OA, Lewis S, Mendiratta-Lala M, King K, Sachdev L, Lee EW, Bruno J, Kamel I, Tolosa C, Kao K, Badawi T, Przybyszewski EM, Quirk L, Nathani P, Haydel B, Leven E, Wong N, Albertian R, Chen A, Aloor FZ, Mohamed IB, Elkheshen A, Marvil C, Issac G, Clinton JW, Woo SM, Yum J, Rieger E, Hutchison AL, Turner DA, Alsudaney M, Hernandez P, Xu Z, Khalid A, Barrick B, Wang B, Tapper EB, Hao W, Singal AG
doi: 10.1016/j.cgh.2024.07.008
Hepatology
Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study
Hepatology
Holmer M, Ingre M, Färkkilä M, Ponsioen C, Mol B, Schramm C, Folseraas T, Wiencke K, Cazzagon N, Catanzaro E, Molinaro A, Nilsson E, Vessby J, Kechagias S, Nyhlin N, Werner M, Bergquist A
doi: 10.1097/HEP.0000000000001351